Martina Brueckmann

Ludolf Krehl Str. 13-17
Mannheim, BW 68167, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 164 publications

Survodutide Once Weekly for the Treatment of Adults with Obesity.

Survodutide Once Weekly for the Treatment of Adults with Obesity.

Journal: The New England journal of medicine

Published: June 08, 2026

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.

Journal: Diabetes, obesity & metabolism

Published: February 12, 2026

Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients: An Analysis From the EMPEROR-Reduced Trial.

Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients: An Analysis From the EMPEROR-Reduced Trial.

Journal: JACC. Heart failure

Published: October 05, 2025

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).

Journal: Diabetes, obesity & metabolism

Published: September 01, 2025

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.

Journal: Diabetes, obesity & metabolism

Published: September 01, 2025

Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.

Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.

Journal: JACC. Heart failure

Published: August 13, 2025

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.

Journal: ESC heart failure

Published: July 11, 2025

Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-Reduced.

Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-Reduced.

Journal: European journal of heart failure

Published: May 26, 2025

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.

Journal: The lancet. Diabetes & endocrinology

Published: May 09, 2025

Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled.

Empagliflozin in Heart Failure and Previous Coronary Revascularization: Insights From EMPEROR-Pooled.

Journal: JACC. Advances

Published: November 13, 2024

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

Journal: The New England journal of medicine

Published: October 25, 2024

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).

Journal: Obesity (Silver Spring, Md.)

Published: September 06, 2024

Showing 1-12 of 164

Last Updated: 09/26/2026